Drug Profile
Infliximab biosimilar - BioXpress Therapeutics
Latest Information Update: 29 Dec 2021
Price :
$50
*
At a glance
- Originator BioXpress Therapeutics
- Class Anti-inflammatories; Anti-TNF monoclonal antibodies; Antipsoriatics; Antirheumatics
- Mechanism of Action Tumour necrosis factor alpha inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Inflammation; Rheumatoid arthritis
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Inflammation in Switzerland (IV, Infusion)
- 04 Nov 2017 No recent reports of development identified for preclinical development in Rheumatoid-arthritis in Switzerland (IV, Infusion)
- 21 Aug 2013 Preclinical trials in Inflammation in Switzerland (IV)